Latest Biotech News

Novartis reported that its Phase III HARBOR study of del-desiran (delpacibart etedesiran) in myotonic dystrophy type 1 did not meet the primary endpoint of video hand opening time (vHOT)...

Definium Therapeutics said its oral LSD-derived candidate DT120 eased anxiety symptoms in a second large Phase 3 trial, reinforcing its case for a regulatory submission for the first psychedelic...

AstraZeneca said its newly approved SERD Etcamah failed to demonstrate benefit in a late-stage Phase III trial intended to support a label expansion into an earlier, untreated setting for advanced...

Electra Therapeutics announced plans to raise up to $341.9 million through an initial public offering to finance clinical development of its inflammatory disorder drug ipsoprubart and its push...

Data from the Phase 1b DeLLphi-308 study presented at the International Association for the Study of Lung Cancer’s 2026 World Conference on Lung Cancer suggest subcutaneous tarlatamab may offer...

MediLink reported Phase 3 results for a Roche-partnered antibody-drug conjugate in small-cell lung cancer, saying the trial met its primary endpoint. However, the company said median overall...

As pharmaceutical tariffs on patented drug products and associated inputs approach a Sept. 29 implementation date, the Biotechnology Innovation Organization (BIO) said investor and company...

A real-world study reported that Nefecon—targeted-release budesonide—reduced proteinuria and helped preserve kidney function in patients with primary IgA nephropathy, including those starting with...

A new report on biopharma venture financing argues corporate venture capital (CVC) is reshaping ownership and funding dynamics, shifting how capital is allocated through Series B and beyond. The...

MediLink reported phase 3 results for a Roche-partnered B7-H3-directed antibody-drug conjugate in small-cell lung cancer, with the study hitting its primary endpoint but trailing a competitor...

Novartis shares took a hit after the company acknowledged failure of its neuromuscular candidate delpacibart etedesiran in a pivotal phase 3 trial, according to reporting on the StockWatch. The...

A wave of new immuno-oncology research is challenging assumptions about how anti-tumor immunity is initiated and sustained. One report highlighted that intratumoral T-cell activation can eliminate...

Interra Health announced support for Medicare patients under its GLP-1 Bridge program, aiming to make monthly GLP-1 therapy more affordable by covering $50 per month. The move targets a key access...

Corporate venture capital is reshaping how biopharma companies get funded, with investors emphasizing “permanent capital” and strategic capabilities. Reporting highlights a British Business Bank...

Helmholtz Munich, Technical University of Munich, and the University of Basel unveiled MemBrain v2, an AI tool that automates 3D membrane analysis in cryo-electron tomography. The study, published...

Scientists reported evidence linking soluble immune marker dynamics to Huntington’s disease progression. In work from Sweden, sCD30 (TNFRSF8) levels measured in spinal fluid declined steadily as...

A Nature Biotechnology study described a new sequencing method that maps RNA isoforms across brain cells with single-cell precision, targeting the long-standing challenge that the same gene can...

A Nature Methods study highlighted MemBrain v2, but other AI-driven therapy design updates signal continued momentum for computational discovery engines. One report describes an AI method that...

In a phase 1b study, tarlatamab was evaluated using a subcutaneous dosing approach for extensive-stage small cell lung cancer. Investigators presented early safety and initial activity data from...

Novartis said its neuromuscular candidate delpacibart etedesiran (del-desiran) failed to meet a primary endpoint in a Phase 3 study (HARBOR, NCT06411288), adding to pressure on the company’s...